Cenegenics’ U.S. locations now offering Cleerly’s AI-enabled approach to personalized heart care
DENVER – JULY 18, 2023 -- Cleerly, the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease, today announced a partnership with Cenegenics, a leading performance health age management platform dedicated to helping people achieve their peak cognitive, physical and metabolic health. Through the partnership, Cenegenics will use Cleerly’s AI-enabled platform to evaluate coronary computed tomography angiography (CCTA) imaging, allowing physicians to identify, characterize and qualify atherosclerosis (plaque) buildup in the walls of heart arteries more easily. The personalized reporting provided through this platform can help providers deliver precision treatment across the continuum of heart disease severity, improving clinical outcomes while drastically reducing patient costs.
“Cleerly is excited to be partnering with Cenegenics to offer preventive heart disease care to its patients,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. “Leveraging our platform, Cenegenics will be able to provide patients with technology that goes beyond the traditional measure of heart disease by analyzing, characterizing and quantifying types of plaque, so they’re able to more accurately determine a patient’s heart attack risk and develop the right treatment plans.”
Cleerly’s CCTA analysis provides physicians information that can allow a more accurate understanding of a patient’s risk of heart attack. The technology provides a detailed vessel-by-vessel evaluation of stenoses and atherosclerosis and is a shift away from how heart disease has traditionally been assessed through the use of indirect surrogate markers of disease. With more than half of all patients who experience a heart attack not showing any symptoms or surrogate markers before the event, this shift in how we evaluate and assess patients is essential.
This partnership will allow Cenegenics to continue with their mission of helping patients take control of their health, using Cleerly’s technology to help prevent heart health problems before it’s too late. Cenegenics has 21 locations across the United States and 8 international locations. Upon launch, Cleerly services will be available in all 21 Cenegenics Centers within the U.S.
“We are pleased to partner with Cleerly across all of our Cenegenics Centers nationally,” said Kristy Berry, CEO of Cenegenics. “As the leaders in performance health age management, Cenegenics sees enormous value in the Cleerly AI-enabled heart health imaging platform. Their four-tiered, personalized coronary analysis presentation will enable and empower our physicians and performance health teams to create preventative heart health programs for our patients.”
Cleerly’s services are now available at all Cenegenics locations nationwide and those interested can visit Cenegenics Locations to learn more and schedule an appointment.
Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly helps enable comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.
For more information, please visit: https://cleerlyhealth.com
About Cenegenics
Founded in 1997, Cenegenics provides the world’s best Performance Health Age Management solution, fueled by sophisticated data, technology, and metabolic science to motivate and inspire, helping people achieve their peak cognitive, physical and metabolic health. Having served over 44,000 patients worldwide through its 25+ year history, Cenegenics takes a comprehensive approach to preventive medicine, enabling patients to live longer, more energized lives.
With 29 locations across the globe and counting, including Beverly Hills, New York City, San Francisco, Chicago, London and Brazil, Cenegenics is on a path to partner with patients wherever they are located.
For more information on Cenegenics and its team of medical professionals, visit https://www.cenegenics.com.
Download: JPG |
Cleerly: March 26, 2024
CREDENCE and PACIFIC-1 study data demonstrate potential power of AI-QCT ISCHEMIA
Cleerly: March 5, 2024
Company’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial
Cleerly: February 22, 2024
FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease
Cleerly
